Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Specificity of four laboratory approaches for cross-sectional HIV incidence determination: analysis of samples from adults with known nonrecent HIV infection from five African countries.

Laeyendecker O, Brookmeyer R, Mullis CE, Donnell D, Lingappa J, Celum C, Baeten JM, Campbell MS, Essex M, de Bruyn G, Farquhar C, Quinn TC, Eshleman SH; Partners in Prevention HSV/HIV Transmission Study Team.

AIDS Res Hum Retroviruses. 2012 Oct;28(10):1177-83.

2.

Evaluation of the false recent classification rates of multiassay algorithms in estimating HIV type 1 subtype C incidence.

Moyo S, LeCuyer T, Wang R, Gaseitsiwe S, Weng J, Musonda R, Bussmann H, Mine M, Engelbrecht S, Makhema J, Marlink R, Baum MK, Novitsky V, Essex M.

AIDS Res Hum Retroviruses. 2014 Jan;30(1):29-36. doi: 10.1089/AID.2013.0055. Epub 2013 Sep 6.

3.

HIV incidence determination in the United States: a multiassay approach.

Laeyendecker O, Brookmeyer R, Cousins MM, Mullis CE, Konikoff J, Donnell D, Celum C, Buchbinder SP, Seage GR 3rd, Kirk GD, Mehta SH, Astemborski J, Jacobson LP, Margolick JB, Brown J, Quinn TC, Eshleman SH.

J Infect Dis. 2013 Jan 15;207(2):232-9. doi: 10.1093/infdis/jis659. Epub 2012 Nov 5.

4.

Effect of CD4+ T cell count and antiretroviral treatment on two serological HIV incidence assays.

Hladik W, Olara D, Mermin J, Moore D, Were W, Alexander L, Downing R.

AIDS Res Hum Retroviruses. 2012 Jan;28(1):95-9. doi: 10.1089/AID.2010.0347. Epub 2011 Mar 11.

PMID:
21314476
5.

Performance of a limiting-antigen avidity enzyme immunoassay for cross-sectional estimation of HIV incidence in the United States.

Konikoff J, Brookmeyer R, Longosz AF, Cousins MM, Celum C, Buchbinder SP, Seage GR 3rd, Kirk GD, Moore RD, Mehta SH, Margolick JB, Brown J, Mayer KH, Koblin BA, Justman JE, Hodder SL, Quinn TC, Eshleman SH, Laeyendecker O.

PLoS One. 2013 Dec 27;8(12):e82772. doi: 10.1371/journal.pone.0082772. eCollection 2013.

6.

Significantly diminished long-term specificity of the BED capture enzyme immunoassay among patients with HIV-1 with very low CD4 counts and those on antiretroviral therapy.

Marinda ET, Hargrove J, Preiser W, Slabbert H, van Zyl G, Levin J, Moulton LH, Welte A, Humphrey J.

J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):496-9.

PMID:
20306555
7.

Factors associated with incorrect identification of recent HIV infection using the BED capture immunoassay.

Laeyendecker O, Brookmeyer R, Oliver AE, Mullis CE, Eaton KP, Mueller AC, Jacobson LP, Margolick JB, Brown J, Rinaldo CR, Quinn TC, Eshleman SH; Multicenter Aids Cohort Study Macs.

AIDS Res Hum Retroviruses. 2012 Aug;28(8):816-22. doi: 10.1089/AID.2011.0258. Epub 2011 Dec 1.

8.

Differential specificity of HIV incidence assays in HIV subtypes A and D-infected individuals from Rakai, Uganda.

Mullis CE, Munshaw S, Grabowski MK, Eshleman SH, Serwadda D, Brookmeyer R, Nalugoda F, Kigozi G, Kagaayi J, Tobian AA, Wawer M, Gray RH, Quinn TC, Laeyendecker O.

AIDS Res Hum Retroviruses. 2013 Aug;29(8):1146-50. doi: 10.1089/AID.2012.0105. Epub 2013 May 29.

9.

Improved testing of recent HIV-1 infections with the BioRad avidity assay compared to the limiting antigen avidity assay and BED Capture enzyme immunoassay: evaluation using reference sample panels from the German Seroconverter Cohort.

Hauser A, Santos-Hoevener C, Meixenberger K, Zimmermann R, Somogyi S, Fiedler S, Hofmann A, Bartmeyer B, Jansen K, Hamouda O, Bannert N, Kuecherer C.

PLoS One. 2014 Jun 3;9(6):e98038. doi: 10.1371/journal.pone.0098038. eCollection 2014.

10.

Antibody maturation and viral diversification in HIV-infected women.

James MM, Laeyendecker O, Sun J, Hoover DR, Mullis CE, Cousins MM, Coates T, Moore RD, Kelen GD, Fowler MG, Kumwenda JJ, Mofenson LM, Kumwenda NI, Taha TE, Eshleman SH.

PLoS One. 2013;8(2):e57350. doi: 10.1371/journal.pone.0057350. Epub 2013 Feb 27.

11.

Impact of HIV subtype on performance of the limiting antigen-avidity enzyme immunoassay, the bio-rad avidity assay, and the BED capture immunoassay in Rakai, Uganda.

Longosz AF, Serwadda D, Nalugoda F, Kigozi G, Franco V, Gray RH, Quinn TC, Eshleman SH, Laeyendecker O.

AIDS Res Hum Retroviruses. 2014 Apr;30(4):339-44. doi: 10.1089/AID.2013.0169. Epub 2013 Oct 25.

12.

Immune responses in Ugandan women infected with subtypes A and D HIV using the BED capture immunoassay and an antibody avidity assay.

Longosz AF, Morrison CS, Chen PL, Arts E, Nankya I, Salata RA, Franco V, Quinn TC, Eshleman SH, Laeyendecker O.

J Acquir Immune Defic Syndr. 2014 Apr 1;65(4):390-6. doi: 10.1097/QAI.0000000000000006.

13.

Detection of recent HIV-1 infection using a new limiting-antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studies.

Duong YT, Qiu M, De AK, Jackson K, Dobbs T, Kim AA, Nkengasong JN, Parekh BS.

PLoS One. 2012;7(3):e33328. doi: 10.1371/journal.pone.0033328. Epub 2012 Mar 27.

14.

Association of recent HIV infection and in-utero HIV-1 transmission.

Taha TE, James MM, Hoover DR, Sun J, Laeyendecker O, Mullis CE, Kumwenda JJ, Lingappa JR, Auvert B, Morrison CS, Mofensen LM, Taylor A, Fowler MG, Kumenda NI, Eshleman SH.

AIDS. 2011 Jul 17;25(11):1357-64. doi: 10.1097/QAD.0b013e3283489d45.

15.

The effect of viral suppression on cross-sectional incidence testing in the johns hopkins hospital emergency department.

Laeyendecker O, Rothman RE, Henson C, Horne BJ, Ketlogetswe KS, Kraus CK, Shahan J, Kelen GD, Quinn TC.

J Acquir Immune Defic Syndr. 2008 Jun 1;48(2):211-5. doi: 10.1097/QAI.0b013e3181743980.

16.

Effect of natural and ARV-induced viral suppression and viral breakthrough on anti-HIV antibody proportion and avidity in patients with HIV-1 subtype B infection.

Wendel SK, Mullis CE, Eshleman SH, Blankson JN, Moore RD, Keruly JC, Brookmeyer R, Quinn TC, Laeyendecker O.

PLoS One. 2013;8(2):e55525. doi: 10.1371/journal.pone.0055525. Epub 2013 Feb 20.

17.

Assessment of recent HIV-1 infection by a line immunoassay for HIV-1/2 confirmation.

Schüpbach J, Gebhardt MD, Tomasik Z, Niederhauser C, Yerly S, Bürgisser P, Matter L, Gorgievski M, Dubs R, Schultze D, Steffen I, Andreutti C, Martinetti G, Güntert B, Staub R, Daneel S, Vernazza P.

PLoS Med. 2007 Dec;4(12):e343.

18.
19.

Investigating the utility of the HIV-1 BED capture enzyme immunoassay using cross-sectional and longitudinal seroconverter specimens from Africa.

Karita E, Price M, Hunter E, Chomba E, Allen S, Fei L, Kamali A, Sanders EJ, Anzala O, Katende M, Ketter N; IAVI Collaborative Seroprevalence and Incidence Study Team.

AIDS. 2007 Feb 19;21(4):403-8.

PMID:
17301558
20.

Short Communication: Low False Recent Rate of Limiting-Antigen Avidity Assay Among Long-Term Infected Subjects from Guangxi, China.

Yu L, Laeyendecker O, Wendel SK, Liang F, Liu W, Wang X, Wang L, Pang X, Fang Z.

AIDS Res Hum Retroviruses. 2015 Dec;31(12):1247-9. doi: 10.1089/aid.2015.0097. Epub 2015 Sep 2.

PMID:
26331573
Items per page

Supplemental Content

Write to the Help Desk